Monopar Therapeutics

MNPR

Biotechnology · Healthcare

Price

$111.12

+2.60 (+2.40%)

Market Cap

$744.4M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count falling — buybacks

−40.6% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 12.5M (2021) → 7.4M (2025)

Monopar Therapeutics is a small clinical-stage biotech company that develops experimental drugs to treat cancer and radiation-related injuries. Its lead programs focus on reducing serious side effects caused by cancer treatments, such as tissue damage from radiation therapy, with patients and hospitals as the end users. The company does not yet sell any approved products.

Monopar does not currently generate meaningful revenue, which is typical for early-stage drug developers. It funds its operations through stock offerings and grants while spending on clinical trials, primarily in the United States. The company has no approved drugs on the market, which means its entire value depends on whether its experimental treatments succeed in clinical trials and eventually win regulatory approval — a process that is costly, slow, and fails more often than it succeeds.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-21.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$9.9B/ year

↑ Rising (+76051% vs prior year)

R&D investment increasing — building for the future

Insider Activity

38.1%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~4 years

$52.5B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$52.5B cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-0.0%

Weak — -0.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.00

Conservative — low debt load (0.00)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial